Dauricine negatively regulates lipopolysaccharide- or cecal ligation and puncture-induced inflammatory response via NF-κB inactivation

Arch Biochem Biophys. 2019 May 15:666:99-106. doi: 10.1016/j.abb.2019.03.018. Epub 2019 Apr 1.

Abstract

Acute lung injury (ALI) is a challenging clinical problem worldwide characterized by severe pulmonary inflammation. Dauricine, extracted from the root of traditional Chinese medicine Menispermum dauricum DC, is employed as anti-inflammatory herbs. In this study, we explored the inhibitory effects of dauricine on lipopolysaccharide (LPS)-induced inflammation in macrophages and LPS- or cecal ligation and puncture (CLP)-induced ALI in C57BL/6 mice. Our in vitro study identified that pretreatment of dauricine dose-dependently inhibited pro-inflammatory cytokines including nitric oxide (NO), interleukin-1β (IL1β), IL6, tumor necrosis factor-α (TNFα), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX2) in LPS-stimulated macrophages. Moreover, dauricine could suppress LPS-mediated nuclear translocation and transcriptional activity of nuclear factor-kappaB (NF-κB) by suppressing the phosphorylation of NF-κB inhibitors (IκB). In vivo studies, administration of dauricine, especially high-dose dauricine, potently improved the survival rate, reduced the production of pro-inflammatory cytokines in serum, and ameliorated ALI induced by LPS or CLP via blockage of NF-κB activation. Collectively, the present study discovers a new biological effect of dauricine in prevention of inflammation, indicating that dauricine can be served as a potential therapeutic agent to treat inflammatory diseases.

Keywords: Acute lung injury; Cecal ligation and puncture; Dauricine; Inflammation; Lipopolysaccharide; NF-κB.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury / drug therapy
  • Acute Lung Injury / etiology
  • Acute Lung Injury / pathology
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Benzylisoquinolines / pharmacology*
  • Cytokines / antagonists & inhibitors
  • Cytokines / metabolism
  • Humans
  • Inflammation / drug therapy*
  • Inflammation / etiology
  • Inflammation / metabolism
  • Inflammation Mediators / antagonists & inhibitors
  • Inflammation Mediators / metabolism
  • Lipopolysaccharides / toxicity
  • Macrophages, Peritoneal / drug effects
  • Macrophages, Peritoneal / metabolism
  • Macrophages, Peritoneal / pathology
  • Medicine, Chinese Traditional
  • Mice
  • Mice, Inbred C57BL
  • NF-kappa B / antagonists & inhibitors*
  • Phytotherapy
  • RAW 264.7 Cells
  • Tetrahydroisoquinolines / pharmacology*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Benzylisoquinolines
  • Cytokines
  • Inflammation Mediators
  • Lipopolysaccharides
  • NF-kappa B
  • Tetrahydroisoquinolines
  • dauricine